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The use of temozolomide (TMZ) has improved the prognosis for glioblastoma multiforme
patients. However, TMZ resistance may be one of the main reasons why treatment fails.
Although this resistance has frequently been linked to the expression of O6-methylguanine-
DNA methyltransferase (MGMT) it seems that this enzyme is not the only molecular mecha-
nism that may account for the appearance of drug resistance in glioblastoma multiforme
patients as the mismatch repair (MMR) complex, P-glycoprotein, and/or the presence of
cancer stem cells may also be implicated.
Methods
Four nervous system tumor cell lines were used to analyze the modulation of MGMT
expression and MGMT promoter methylation by TMZ treatment. Furthermore, 5-aza-2’-
deoxycytidine was used to demethylate the MGMT promoter and O(6)-benzylguanine to
block GMT activity. In addition, MMR complex and P-glycoprotein expression were studied
before and after TMZ exposure and correlated with MGMT expression. Finally, the effect of
TMZ exposure on CD133 expression was analyzed.
Results
Our results showed two clearly differentiated groups of tumor cells characterized by low
(A172 and LN229) and high (SF268 and SK-N-SH) basal MGMT expression. Interestingly,
cell lines with no MGMT expression and low TMZ IC50 showed a high MMR complex
expression, whereas cell lines with high MGMT expression and high TMZ IC50 did not
express the MMR complex. In addition, modulation of MGMT expression in A172 and
LN229 cell lines was accompanied by a significant increase in the TMZ IC50, whereas no
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differences were observed in SF268 and SK-N-SH cell lines. In contrast, P-glycoprotein
and CD133 was found to be unrelated to TMZ resistance in these cell lines.
Conclusions
These results may be relevant in understanding the phenomenon of TMZ resistance, espe-
cially in glioblastoma multiforme patients laking MGMT expression, and may also aid in the
design of new therapeutic strategies to improve the efficacy of TMZ in glioblastoma multi-
forme patients.
Introduction
Glioblastoma multiforme (GBM), the most common astrocytic tumor, representing about 65%
of all adult nervous system tumors, is characterized by a high aggressiveness, with an average
survival period of less than 15 months [1–4]. Current treatment options, including surgery,
radiation therapy, and chemotherapy [2], shows a limited response due to blood-brain barrier
(BBB) protection, the absence of a lymphatic drainage system, and development of drug resis-
tance [5]. In this context, a better understanding of GBM resistance mechanisms may lead to
the development of new therapeutic strategies.
Temozolomide (TMZ), a second-generation imidazotetrazine lipophilic prodrug, has
improved the prognosis for GBM patients because it can cross the BBB and induce glioblas-
toma cell death by introducing alkyl groups into DNA [6]. Temozolomide is highly stable at
stomach acid pH but spontaneously undergoes hydrolysis to the active metabolite MTIC [5-
(3-dimethyl-1-triazenyl)imidazole-4-carboxamide] at physiological pH, thus releasing the
drug's activity in the tumor tissue [7]. The drug forms O6-methylguanine adducts that intro-
duce mispairs with thymine, which cannot be repaired thereby inducing the formation of sin-
gle- and double-strand DNA breaks and triggering apoptosis and senescence mechanisms in
glial cells [8,9]. However, the presence of some drug-resistance mechanisms appears to be
responsible for the therapeutic failure of TMZ in GBM patients.
Two candidates, namely O6-methlyguanine-DNA-methyltransferase (MGMT) and the
mismatch repair (MMR) system, have been associated with ineffective GBM therapy, although
their relationship is not yet clear. The MGMT repair protein protects the cellular genome from
the mutagenic effects of alkylating agents such as TMZ by removing the O6-alkylguanine DNA
adduct. This adduct is transferred from the alkyl group to one of its own cysteine residues and
normal guanine is restored [10], thereby reducing the effect of TMZ. MGMT promoter methyl-
ation status is responsible for regulating MGMT expression and has been correlated with
increased GBM patient survival [11] although subsequent studies suggested that this associa-
tion is inconclusive [12]. However, MMR is critical for the maintenance of replication fidelity
and for inducing appropriate cellular responses to DNA damage [13]. The functions of this
protein complex, which includes the proteins codified by the genes MLH1, MSH2, MLH3,
MLH6 and PMS2 [14], are not fully known. Moreover, an MMR deficiency has been correlated
with genetic instability in colorectal cancer [9,14]. In GBM, TMZ treatment induces DNA
lesions such as O6-MeG which cannot be repaired by MGMT, with the MMR system causing
double-strand DNA breaks and apoptosis [15]. As such, the MMR complex must work prop-
erly in order for TMZ to carry out its cytotoxic function. Indeed, Goellner et al. [16] showed a
relationship between TMZ resistance and MMR failure in GBM patients. In addition, some
authors have attempted to correlate TMZ resistance in GBM patients to the presence of P-
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gp, P-glycoprotein; 5-Aza, 5-Aza-20-deoxycytidine;
O6-BG, O(6)-benzylguanine; CSC, Cancer stem
cells; MSP, Methylation-specific PCR; M, Methylated;
UM, Unmethylated.
glycoprotein (P-gp) acts as an efflux pump that expels the drug from the cell, thus reducing its
effectiveness, in the membrane of tumor cells [10,17]. This phenomenon, known as multidrug
resistance phenotype (MDR), results in the survival of tumor cells despite drug treatment and
the subsequent failure of chemotherapy against several types of tumor [18]. Finally, Cancer
Stem Cells (CSC) have also been related to tumor resistance to chemotherapy and radiother-
apy. CD133 expression may be used to detect and evaluate the population of CSCs inside cer-
tain tumors, including GBM [19]. However, although the presence of high amounts of CSCs in
tumors appears to be associated with a worse prognosis and a reduced response to treatment,
the exact correlation is still unclear [20].
The aim of this study was to analyze the relevance of MGMT, the MMR system and P-gp in
the development of resistance against TMZ in tumor cell lines A172, LN229, SF268 and SK-N-SH.
Interestingly, we have demonstrated a significant correlation between MGMT andMMR complex
expression such that cell lines with noMGMT expression and a low TMZ IC50 presented high
MMR complex levels. In contrast, cell lines with a high MGMT expression and a high IC50 against
TMZ did not express the MMR complex. In addition, neither P-gp nor CD133 expression
appeared to play a relevant role in the TMZ resistance phenomenon of these cell lines. Thus, the
status of the MMR complex could be related to MGMT activity in GBM patients as both are
related to TMZ resistance. This connection could have clinical importance in terms of explaining
TMZ resistance in GBM patients and, therefore, the differences in their responses to treatment.
Methods
Cell lines
A172, LN229 (from American Type Culture Collection: CRL-1620™ and CRL-2611™, respec-
tively) and SF268 (from Scientific Instrument Center, Granada University) human glioblas-
toma cell lines and the SK-N-SH human neuroblastoma cell line (from American Type Culture
Collection: HTB-11™) were grown in Dulbecco’s Modified Eagle’s Medium (Sigma, St. Louis,
MO, USA), supplemented with 10% fetal bovine serum (FBS) and 1% antibiotics (penicillin
and streptomycin). Cells were maintained in monolayer culture at 37°C under a humidified
atmosphere containing 5% CO2.
Drugs and reagents
Temozolomide (TMZ), 5-aza-2’-deoxycytidine (5Aza) and O(6)-benzylguanine (O6-BG) were
purchased from Sigma-Aldrich. Aliquots of TMZ dissolved in DMSO (20 mg/ml) and prepared
in serum-free culture medium (10 mg/ml) were protected from light and stored at –20°C.
O6-BG stocks were dissolved in methanol (10 mg/ml) and stored at room temperature.
In vitro drug treatments
Temozolomide treatment of all tumor cell lines comprised a double cycle (3 days of drug expo-
sure followed by 3 days without drug) using the previously determined IC50 dose. Cell lines
exposed to the first and second TMZ cycle (named -1C and -2C, respectively) were subsequently
subjected to further studies at the IC50 for TMZ. 5-Aza was used in de-methylation studies at a
concentration of a 30 μM for A172 and LN229 and 10 μM for SF268 and SK-N-SH. In addition,
SF268 and SK-N-SH cell lines were exposed to 30 μMO6-BG prior to TMZ treatment.
Cytotoxicity assays
Cell lines exposed to TMZ (with or without 5-Aza or O6-BG pre-treatment) were grown in
24-well plates (Sigma) under standard culture conditions for 6 days. Cytotoxicity was
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determined using the sulphorhodamine-B (SRB) method. Briefly, the cells were fixed with 10%
trichloroacetic acid for 20 min at 4°C then washed three times with water. After 24 hours, cells
were stained for 30 min at room temperature with 0.4% SRB dissolved in 1% acetic acid and
then washed three times with 1% acetic acid. The plates were air-dried and the dye solubilized
with 300 ml/well of 10 mM Tris base (pH 10.5) for 10 min on a shaker. The optical density of
each well was measured spectrophotometrically using a Titertek multiscan colorimeter (Flow,
Irvine, California) at 492 nm.
Methylation-specific PCR analysis
DNA was extracted from culture cells using the QIAamp DNAMini Kit (EpiTect Bisulfite kit,
Qiagen, Maryland, USA) in accordance with the manufacturer's standard recommendations.
Thus, 2 μg of DNA from each cell line was denatured, modified, and purified using the EpiTect
Bisulfite kit (Qiagen, Maryland, USA). The MGMT promoter CpG islands methylation status
of different cell lines was based on chemical modification of unmethylated cytosine with bisul-
fite to uracil. Methylation-specific PCRs (MSP) were performed using specific primers for
either methylated or unmethylated DNA in the MGMT promoter. Primer sequences for
MGMT were 5'-TTTGTGTTTTGATGTTTGTAGGTTTTTGT-3' (forward primer) and 5'-
AACTCCACACTCTTCCAAAAACAAAACA-3' (reverse primer) for the unmethylated (UM)
reaction and 5'-TTTCGACGTTCTAGGTTTTCGC-3' (forward primer) and 5'-GCACTCT
TCCGAAAACGAAACG-3' (reverse primer) for the methylated (M) reaction. Agarose electro-
phoresis visualization by ethidium bromide and UV illumination was performed after PCR.
High-resolution MGMTmethylation analysis
The high-resolution MGMTmethylation analysis of bisulfite samples was performed using
high-sensitive SYBR1 Green (KapaBiosystems, Boston, USA) at the Center for Genomics and
Oncological Research (GENYO, Granada). The reaction was conducted using an Eco Real-
Time PCR System (Illumina, CA, USA) and data were analyzed using the Eco Real-Time PCR
System v4.0 software. Methylated EpiTect Control DNA, methylated and unmethylated Epi-
Tect Control DNA, (Qiagen, Madrid, Spain) were used for the methylation curve, with methyl-
ated-unmethylated ratios of 0, 0.25, 0.5, 0.75, and 1. All samples and the methylation curve
were analyzed using a pair of primers for the specific region.
mRNA expression analysis
Total RNA was extracted using an RNA purification system (RNeasy, Qiagen). Reverse tran-
scription-PCR was performed with 1.5 μg of isolated total RNA and synthesized to cDNA in a
20 μl reaction system using reverse transcriptase (Promega) with oligo-dT primers according
to the manufacturer’s instructions. cDNA was used to determine MGMT expression before
and after 5Aza treatment with the following primers: Fw 5'- TCACGGCCAGTCCTCCGGAG
-3' and Rw 5'- GTTCCCCGTGCCGGCTCTTC -3'. PCR was performed under classical con-
ditions with a melting temperature of 58°C. Amplified products were separated by electropho-
resis on a 3% agarose gel and visualized under UV illumination. In addition, cDNA was
amplified by real-time PCR in 96-well plates using an Applied Biosystem 7500 system (Applied
Biosystems, Life Technologies). The total reaction volume of 20 μl contained 20 ng cDNA,
1xTAqMan Universal PCR Mastermix (Applied Biosystems, Life Technologies), and 1x Taq-
Man Gene Expression assay (Applied Biosystems, Life Technologies). The PCR was run at
50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 s and 60°C for 60 s. Each sample
was analyzed using the TaqMan Gene Expression AssaysMGMT (Hs01037698_m1 Applied
Biosystems, Life Technologies), ABCB1 (Hs00184500_m1 Applied Biosystems, Life
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Technologies) as well as an endogenous control GADPH (Applied Biosystems, Life Technolo-
gies). For MMR genes (Table 1), real-time PCR was carried out as described previously using
Sybergreen reagent according to the manufacturer's instructions (Takara, Clontech Laborato-
ries, Inc. USA). Ct-values for all samples were determined automatically with the default set-
ting using StepOne Software V2.0 (Applied Biosystems, Life Technologies). Gene expression
levels were calculated using the ΔCt method: ΔCt = mean value Ct (mRNA reference) −mean
value Ct (mRNA of interest). Normalised ΔCT (delta cycle threshold) values were obtained by
subtracting the Ct for GADPH from that for the gene of interest. The relative mRNA expres-
sion of the gene of interest corresponded to the value 2ΔCt.
Western blot analysis
Cells were washed twice with phosphate-buffered saline (PBS) and lysed with a lysis buffer
(Trizma base 50 mM, sacarose 0.25 mM, EDTA 5 mM and triton X-100 0.5%, pH 7.4). Protein
concentration was determined using Bradford Reagent (Bio-Rad) after sonication. Thus, 25 μg
of protein was electrophoretically separated by 12% SDS-PAGE and transferred to nitrocellu-
lose membranes. These membranes were blocked for 30 min at room temperature in 5% (w/v)
milk powder in PBS containing 0.1% Tween 20, co-incubated overnight at 4°C with the pri-
mary antibodies (MGMT 1:200, β-actin 1:10000 dilution), washed three times with 0.1%
Tween 20 in PBS, and incubated for 1 h with a horseradish peroxidase-conjugated (HRP) goat
anti-mouse secondary antibody 1:2500 (Santa Cruz Biotechnology). Proteins were visualized
using the ECL system (Amersham Biosciences, USA) in the LAS-4000 mini equipment. Fur-
ther analysis, as well as image processing and quantification of the bands, was performed using
the program ImageQuant Las-4000. MGMT expression was normalized relative to the β-actin
level of the tumor.
Flow cytometry analysis
The cell-cycle distribution was determined by flow cytometry. Thus cells were treated with
TMZ (IC50 doses for 120 hour), harvested, and fixed in 70% (v/v) cold ethanol for 20 minutes.
They were then pelleted, washed once with PBS and resuspended in propidium iodide (PI)
Table 1. Primer sequences used to analyzeMMR.
Primer name Sequence
MLH1-F TTC GTG GCA GGG GTT ATT CG
MLH1-R GCC TCC CTC TTT AAC AAT CAC TT
MSH2-F GCT GGA AAT AAG GCA TCC AAG G
MSH2-R CAC CAA TGG AAG CTG ACA TAT CA
MSH3-F TGG AAA ATG ATG GGC CTG TTA AA
MSH3-R AGA CAT TCC CAG ATC ACT TCC T
MSH6-F AGC TTA AAG GAT CAC GCC ATC
MSH6-R AAG CAC ACA ATA GGC TTT GCC
PMS2-F GAA GGT TGG AAC TCG ACT GAT
PMS2-R CGC ACA GGT AGT GTG GAA AA
GADPH-F TGC ACC ACC AAC TGC TTA GC
GADPH-R GGC ATG GAC TGT GGT CAT GAG
All primers are written in a 5' to 3' direction and grouped according to pairs. F, forward primer; R, reverse
primer.
doi:10.1371/journal.pone.0140131.t001
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solution (50 μg/mL PI, 0.5 mg/mL RNase staining buffer) for 30 min in the dark. Data were col-
lected and analyzed using the Cellfit program with a FACScan flow cytometer (FACSCanto II
Cytometer; BD Biosciences, San Jose, CA). In addition, CD133 marker for cancer stem cells
were also studied by FACScan. Cells were removed from culture using a nonenzymatic cell dis-
sociation solution (Sigma-Aldrich, Madrid, Spain) and washed with PBS. Approximately
2 × 105 cells were incubated with primary CD133 antibody directly coupled to phycoerythrin
(Miltenyi Biotec, Bergisch Gladbach, Germany) for 15 minutes in the dark at room tempera-
ture. Isotypic controls were used to establish the right gating.
Statistical analysis
Statistical evaluations were carried out using SPSS statistical software, version 16.0 (SPSS Inc.,
Chicago, IL, USA). The level of statistical significance was set at p< 0.05 for all tests. Experi-
mental data were expressed as mean ± standard deviation (SD) and the results compared using
Student’s t-test.
Results
Temozolomide IC50 in tumor cell lines
Determination of the IC50 for TMZ in different cell lines gave values ranging from 14.1 to
234.6 μM that fell into two clearly differentiated groups (Fig 1A): cell lines with low IC50 values
(< 50 μM), which included A172 (14.1 ± 1.1 μM) and LN229 cells (14.5 ± 1.1 μM), and those
with high IC50 values (> 100 μM), which included SF268 (147.2 ± 2.1 μM) and SK-N-SH cells
(234.6 ± 2.3 μM). Analysis of the modulation of TMZ toxicity using two cycles of treatment
demonstrated that the TMZ IC50 increased significantly in cell lines with a low basal IC50,
whereas no modulation was observed in cell lines with a high basal TMZ IC50 (Fig 1B). In fact,
LN229 and A172 cell lines reached a TMZ IC50 35.3 (547.4 ± 2.6 μM; p =< 0.0001) and 5.5
times (77.5 ± 1.8 μM; p = 0.0028) higher, than their respective basal values (Fig 1B).
Cell cycle and TMZ treatment
The cell cycle of the tumor cell lines were studied before and after TMZ treatment using the
previously determined values for TMZ IC50. As shown in Fig 2A, cell-cycle phases in the A172
cell line (76.27% in G1, 22.15% in S, and 1.58% in the G2/M phase) were modified by TMZ
treatment which induced a significant decrease in the G1 phase (30.37%) and an increase in
the G2/M and S phases (48.24% and 21.39%, respectively). Similar results were observed for
the LN229 cell line (Fig 2B) with TMZ exposure inducing a reduction in the G1 phase (from
58.34% to 37.99%) and an increase in the G2/M phase (from 1.93% to 23.53%). No significant
modification was observed in the S phase. In the SF268 cell line (Fig 2C), TMZ treatment
induced a significant increase in the S phase (from 22.41% to 31.52%) at the expense of the G1
phase, whereas no modifications were observed in the G2/M phase. In the SK-N-SH cell line
(Fig 2D), TMZ treatment caused cells to appear in the G2/M phase (21.1%), a decrease in the S
phase from 32.39% to 22.48%, and a minor variation in the G1 phase (from 66.9% to 64.89%).
These cells were also subjected to two TMZ cycles in order to observe modulation in the cell
cycle distribution. SF268 cells (Fig 2C) showed an S phase increase (from 22.41% to 58.57%)
and a G1 reduction (from 77.59% to 40.27%). There was almost no population in the G2/M
phase during TMZ treatment for this cell line. In A172 cells (Fig 2D), TMZ treatment caused a
decrease in the G2/M phase (20.4%) and increases in the S phase (from 21.39% to 36.16%) and
the G1 phase (from 30.37% to 43.80%). For the rest of the cell lines, consecutive exposures to
TMZ had a little effect on the behavior of the cell cycle.
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Fig 1. Temozolomide toxicity. A) Relative growth rates (RGR) for tumor cell lines treated with TMZ. B) Relative growth rates for tumor cell lines before and
after TMZ cycling treatment (B: basal cells; 1C: first TMZ cycle; 2C: second TMZ cycle). SF268 and SK-N-SH lines did not reveal any IC50 variation, whereas
A172 and LN229 showed a large increase in TMZ IC50. All data represent the mean value ± SD of triplicate cultures.
doi:10.1371/journal.pone.0140131.g001
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Fig 2. Cell cycle modulation induced by TMZ treatment.Modulation of the cell cycle (G1, S and G2) by TMZ treatment in A172 (A), LN229 (B), SF268 (C)
and SK-N-SH (D) cell lines. The number of cells in the G1-, S or G2-phase is given as percentages of the total cell population.
doi:10.1371/journal.pone.0140131.g002
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Modulation of MGMT promoter methylation by TMZ
The MGMT promoter CpG island methylation percentage was determined before and after
treatment of each cell line with TMZ (Fig 3A). The A172 and LN229 cell lines (with low TMZ
IC50 values) showed a high percentage of promoter methylation, reaching 100% in the LN229
line and 75–100% in the A172 cell line. No significant changes were detected in either of these
lines after TMZ treatment. In contrast, a lower percentage of promoter methylation was
detected in untreated SF268 (50–75%) and SK-N-SH (75%) cell lines (with high TMZ IC50 val-
ues). After TMZ treatment, SK-N-SH showed a significant decrease to 0–25% after the second
cycle of TMZ. However, no change in promoter methylation percentage was observed for the
SF268 cell line.
Modulation of MGMT expression after TMZ treatment
Real-time PCR analysis showed a significant level of MGMT expression in SF268 and
SK-N-SH cell lines (with high TMZ IC50 values), whereas no MGMT expression was observed
in the A172 and LN229 cell lines (with low TMZ IC50 values; Fig 3B). A significant decrease in
MGMT expression after the second cycle of TMZ treatment was detected in SF268 (70%) and
SK-N-SH cell lines (80%; Fig 3B). In contrast, the A172 and LN229 cell lines, which exhibit no
basal MGMT expression, showed a slight increase in MGMT after TMZ administration but
expressed at very low levels compared to both SF268 and SK-N-SH cell lines (Fig 3B).
The MGMT protein levels in cell lines before and after TMZ treatment were detected using
the western blot technique. Our results demonstrated that MGMT expression in both SF268
and SK-N-SH cell lines (Fig 3C) increased approximately three-fold after TMZ treatment (Fig
3C). In contrast, MGMT protein expression in the A172 and LN229 cell lines was barely
detectable despite TMZ treatment (data not shown; Fig 3C).
Modulation of MGMT expression by 5Aza and O6BG treatment
To determinate the relevance of MGMT in the modulation of TMZ toxicity, 5-Aza was used to
induce MGMT expression and O6-BG to block its activity. As shown in Fig 4A, 5-Aza treat-
ment induced an increase in MGMT protein expression in both SF268 and SK-N-SH cell lines,
which was quantified by densitometry (25% and 50%, respectively) whereas only, a slight mod-
ulation of MGMT expression was observed in A172 and LN229 cell lines (Fig 4A). In addition,
cell lines exposed to 5-Aza were assayed to determine the variation in the TMZ IC50. As shown
in Fig 4B, A172 and LN229 cell lines showed a significant increase in the TMZ IC50 (A172
increased from 14.1 ± 1.1 μM to 66.84 ± 1.6 μM; LN229 increased from 14.5 ± 1.1 μM to
66.93 ± 1.6 μM; p =< 0.0001 and p =< 0.0001, respectively) whereas, no significant variation
in TMZ IC50 was observed for SF268 and SK-N-SH cell lines (142 ± 1.1 μM and 238 ± 1.1 μM,
respectively; p = 0.3875; Fig 4B).
O6-BG was used to silence MGMT only in those cells which expressed MGMT (SF268 and
SK-N-SH). As shown in Fig 5A, O6-BG treatment completely inhibited MGTM expression in
both SF268 and SK-N-SH cell lines even after exposure to TMZ treatment. Furthermore, cell
lines treated with O6-BG were tested using cytotoxicity assays to determine any variation in
the TMZ IC50. Interestingly, no significant changes in the TMZ IC50 value were detected com-
pared to that for untreated cells (p = 0.098; Fig 5B).
Modulation of MMR expression by TMZ treatment
Real-time PCR was used to determine the expression of five genes for the MMR system
(MLH1, MSH2, MSH3, MSH6 and PMS2) in tumor cell lines. The highest level of MMR
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Fig 3. Analysis of MGMT promoter methylation andMGMT expression levels. A) Modulation of the MGMT promoter methylation percentage in tumor
cell lines before and after TMZ treatment. B) Real-time PCR analysis of MGMT expression before and after TMZ treatment. Showing relative expression of
MGMT compared with SK-N-H cell line. C) Western blot analysis of MGMT protein expression in tumor cell lines before and after TMZ treatment. Beta-actin
expression was used as a control. The graphs on the right show the densitometry of the MGMTWestern blot analysis in SF268 and SK-N-SH cell lines before
and after TMZ treatment. B: basal cells; 1C: first TMZ cycle; 2C: second TMZ cycle. All data represent the mean value ± SD of triplicate cultures.
doi:10.1371/journal.pone.0140131.g003
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Fig 4. Modulation of MGMT expression by 5-Aza. A) Densitometric analysis of the effect of 5-Aza for each cell line showing relative expression of MGMT
compared with beta-actin under each experimental condition. Western blot analysis of MGMT expression after 5-Aza exposure in tumor cell lines. Beta-actin
expression was used as a control. B) Relative growth rates of tumor cell lines before and after 5-Aza exposure. B: basal cells, 5Aza: cell line treated with
5-Aza. All data represent the mean value ± SD of triplicate cultures.
doi:10.1371/journal.pone.0140131.g004
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Fig 5. Modulation of MGMT expression by O6-BG in SF268 and SK-N-SH tumor cell lines. A) Western blot analysis of the MGMT expression after
treatment with TMZ, O6-BG and both TMZ + O6-BG. B) Relative growth rates of SF268 and SK-N-SH cell lines with and without O6-BG treatment after TMZ
treatment. B: basal cells, O6BG: cell line treated with O6-BG. All data represent the mean value ± SD of triplicate cultures.
doi:10.1371/journal.pone.0140131.g005
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subunit expression was observed in A172 and LN229 cell lines, whereas such expression was
practically undetectable in SF268 and SK-N-SH lines (Fig 6A). After TMZ treatment, the
MSH2 and MSH6 subunits decreased in A172 (90%) and LN229 (40%) cell lines (Fig 6B)
whereas, the SF268 cell line presented a decrease in the quantity of all MMR subunits (except
MLH1; Fig 6B). For SK-N-SH, all MMR subunits increased in number (except MLH1, which
was practically null; Fig 6B). Consequently, our results demonstrate that TMZ produced an
overall decrease in most of the MMR complexes expressed, thus inducing a reduction in their
effective functional capacity.
Modulation of P-glycoprotein expression by TMZ treatment
P-glycoprotein expression was determined by Western blot for all tumor cell lines. The resis-
tant human colorectal cancer cell line HCT-15 which endogenously expresses of P-gp, was
used as a control. As shown in Fig 7A, all tumor cell lines were negative for P-gp expression.
TMZ treatment induced an increases in P-gp expression in all tumor cell lines, with only
LN229 and SF268 cell lines showing a decrease after the second TMZ cycle (Fig 7B). To deter-
mine the relevance of P-gp expression as regards TMZ cytotoxicity, verapamil was used to
block P-gp before determining the TMZ IC50. As shown in Fig 7B, cell lines with no MGMT
expression (A172 and LN229) did not present any changes in TMZ IC50 after verapamil treat-
ment (p = 0.3875), whereas cell lines with high levels of MGMT expression (SF268 and
SK-N-SH) showed a significant increase in the value of TMZ IC50 (from 147.2 ± 2.1 μM to
276 ± 2.4 μM in SF268 and from 234.6 ± 2.3 μM to 318.2 ± 2.5 μM in SK-N-SH; p = 0.0379 and
p =< 0.0001, respectively).
CD 133 expression and TMZ treatment
In order to estimate the percentage of cancer stem cells in the cancer cell population after per-
forming two TMZ cycles, the expression of the cancer stem cell marker CD133 was evaluated.
Our results showed a low percentage of CD133 positive (CD133+) population in all cell lines
under basal conditions (3.23 ± 2.57% in A172; 3.40 ± 1.40% in LN229; 2.13 ± 0.28% in SF268
and 3.06 ± 1.85% in SK-N-SH) (Fig 8). Interestingly, a significant increase in the CD133+ popu-
lation was detected after the first TMZ cycle in all tumoral cell lines (25.23 ± 3.67% in A172;
22.13 ± 7.13% in LN229; 13.63 ± 3.82% in SF268 and 20.73 ± 8.90% in SK-N-SH). A further
increase in CD133+ population was observed after the second TMZ cycle in SK-N-SH
(37.67 ± 2.54%) while the other cells lines showed a slight decrease compared to the first cycle,
but all of them maintained a CD133+ higher percentage than those observed at baseline
(19.10 ± 5.93% in A172, 23.27 ± 2.90% in LN229 and 8.97 ± 3.25% in SF268). These results are
statistically significant at A172, LN229 and SK-N-SH cell lines with a p value of 0.025, 0.016
and 0.001 respectively. The only cell line which shows a no significant p value is SF268 with a p
value of 0.060. These results are similar to those obtained by determining CD133 expression by
RealTime (S1 Fig).
Discussion
Althought the use of TMZ represented a moderate improvement in the prognosis of GBM
patients (a survival rate increase of around 20%), the development of drug resistance is one of
the main causes of treatment failure [21]. To the molecular mechanism(s) underlying this drug
resistance phenomenon remains unclear [22]. TMZ resistance has typically been related to the
presence of the enzyme MGMT, with the modulation of MGMT expression appearing to be
regulated by MGMT gene promoter methylation. Indeed, some in vivo studies have demon-
strated TMZ treatment to be more effective when combined with a methylated MGMT gene
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Fig 6. Modulation of MMR expression by TMZ treatment. A) Real-time PCR analysis of MMR gene expression levels (MLH1, MSH2, MSH3, MSH6 and
PMS2) in tumor cell lines. B) Modulation of MMR gene expression levels after TMZ treatment in tumor cell lines. B: basal cells; 1C: first TMZ cycle; 2C:
second TMZ cycle. All data represent the mean value ± SD of triplicate cultures.
doi:10.1371/journal.pone.0140131.g006
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Fig 7. Modulation of P-gp expression by TMZ treatment. A) Real-time PCR analysis of P-gp expression levels in tumor cell lines. The TMZ-resistant
HCT15 cell line was used as a control. B) Modulation of P-gp expression by TMZ treatment in tumor cell lines. C) Relative growth rates after exposure to TMZ
in tumor cell lines before and after verapamil (V) treatment. B: basal cells; 1C: first TMZ cycle; 2C: second TMZ cycle. All data represent the mean value ± SD
of triplicate cultures.
doi:10.1371/journal.pone.0140131.g007
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promoter that induces protein silencing [11,23,24]. However, some studies have indicated that
this correlation does not hold true in all cases. Thus, Hegi et al. [25] concluded that there is no
clear relationship between patients with methylated MGMT promoter and a favorable response
to TMZ treatment, and Yin et al. [26] determined the predictive but not prognostic value of
Fig 8. Modulation of CD 133 expression by TMZ treatment. A) Flow cytometry analysis of percentages of CD133 positives in tumor cell lines using TMZ
treatment B: basal cells, 1C: first TMZ cycle; 2C: second TMZ cycle. Data were calculated from three independent experiments. B) Representative flow
cytometry data for CD133 expression. SSC: side-scattered light.
doi:10.1371/journal.pone.0140131.g008
Temozolomide Resistance in Glioblastoma Cells
PLOS ONE | DOI:10.1371/journal.pone.0140131 October 8, 2015 16 / 23
MGMT promoter methylation status in elderly GBM patients after TMZ treatment. Other
authors, such as Wick et al. [27], indicated the need to combine MGMT with other biomarkers.
These contradictory findings indicate that the MGMT protein in GBM patients may not be the
only DNA repair mechanism involved in the response to alkylating agents, with other repair
mechanisms possibly being involved.
Our in vitro results reveal a significant association between MGMT expression in tumor
cells and TMZ resistance. Indeed, SF268 and SK-N-SH cell lines, which are characterized by
high levels of MGMTmRNA and protein expression, showed a pronounced resistance to TMZ
(TMZ IC50 of 147.2 ± 2.1 μM and 234.6 ± 2.3 μM, respectively), whereas A172 and LN229 cell
lines which exhibit no MGMT expression, both have low TMZ IC50 values (14.1 ± 1.1 μM and
14.5 ± 1.1 μM respectively). Similar results were observed by Gaspar et al. [28], who obtain
TMZ IC50 values of between 10 and 20 μmol/L for A172 and LN229 cell lines, thereby estab-
lishing a direct correlation between MGMTmethylation and TMZ sensitivity. Subsequent
studies by Yoshino et al. [29] found that low MGMT expression levels in A172, U-87MG, and
U-251MG cell lines correlated with low TMZ IC50 concentrations (< 100 μM), whereas high
MGMT expression in T98G and U-138MG cell lines was associated with high IC50 values
(> 350 μM). Interestingly, cell lines that do not express MGMT showed an exponential
increase of TMZ resistance after two TMZ treatment cycles. Thus, the LN229 cell line, which
has a low basal TMZ IC50 (14.5 ± 1.1 μM), has exhibited a TMZ IC50 of 109.4 ± 1.9 and
547.4 ± 2.6 μM after the first and second TMZ cycles, respectively. Conversely, cell lines with
high levels of MGMT expression, such as SF268 and SK-N-SH, maintained their basal TMZ
IC50 despite two TMZ cycles (234.6 ± 2.3 μM and 147.2 ± 2.1 μM, respectively). This phenome-
non has also been described in the generation of resistant GBM cell lines [30,31].
The negative correlation between MGMTmRNA and protein levels in some cell lines such
as SF268 and SK-N-SH supports the results of some authors [32,33] who described serious dif-
ficulty in correlating methylation and MGMT expression. It is known that MGMT protein is
depleted by TMZ in a dose dependent form and that this enzyme is degraded by ubiquitination
mechanisms. When the alkylating agent is added, the cell experiences an increasing demand
for MGMT protein, generating a greater amount of mRNA which is quickly translated into
protein. This phenomenon could explain the imbalance between MGMTmRNA and protein
levels after TMZ exposure, although more experimentation is necessary to clarify the regulation
of the MGMT expression mechanism.
After determining TMZ IC50 in tumor cells, we also analyzed the modulation of the cell
cycle as this drug, like most DNA-damaging chemotherapeutic agents, induces cell cycle
arrest [34]. Our results showed a G2/M blockage in A172 and LN299 cell lines after TMZ
treatment (46% and 20%, respectively). In contrast, SF268 and SK-N-SH cell lines, both of
which exhibit high TMZ resistance, showed no significant differences after TMZ exposure
with respect to untreated cells. The relevance of these cell cycle modifications will be dis-
cussed later.
To determine the relationship between MGMT promoter gene methylation, MGMT expres-
sion, and TMZ treatment, we analyzed the methylation status of the promoter in all tumor cell
lines before and after TMZ treatment. It is clear that cell lines with low TMZ IC50 concentra-
tions experienced a high percentage of promoter methylation, whereas this percentage was
much lower in cell lines with a high TMZ IC50. However, no significant changes in promoter
methylation were detected in either the A172 or LN229 cell lines after TMZ treatment. Further
to this, only small changes were noted in the SF268 cell line. SK-N-SH cells, with a methylation
range of 75–100%, were the only cell line with a gradual loss of MGMT promoter methylation,
decreasing to 25–50% after the first TMZ cycle and then 0–25% after the second. As stated
above, it is difficult to correlate methylation status with MGMT expression. In fact, Fig 3 shows
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a significant increase in MGMTmRNA expression in A172 and LN229 cell lines without any
variations in MGMT promoter methylation. This could be explained by the heterogeneity of
the tumor cell lines which means different cell populations may have different methylation pat-
terns and therefore different MGMT expression levels (including a very low MGMT amount).
Hence the MGMTmRNA increase could be induced by some population cells without cell
lines that express MGMT in the basal form. Therefore, no change in the methylation pattern
could be observed, probably because it did not occur as such. Interestingly, analysis of MGMT
expression showed a decrease in SF268 and SK-N-SH and a very small increase in A172 and
LN229 cell lines. Thus, in light of these results, the correlation between methylation variation
and MGMT expression levels remains unclear.
In this context, experiments were performed with 5-Aza and O6-BG. Treatment with
5-Aza, which can demethylate the MGMT promoter [35], increased MGMT expression in
tumor cell lines. Interestingly, the TMZ IC50 for A172 and LN229 cell lines (with no basal
MGMT expression) suffered a significant increase (from 14 ± 1.1 μM to 66 ± 1.6 μM p =<
0.0001), whereas no modulation of TMZ IC50 was observed for the SF268 and SK-N-SH lines,
which have a high basal MGMT expression. Treatment with O6-BG, which is capable of block-
ing MGMT action [28], decreased MGMT protein levels in these latter cell lines, as shown by
Western blot analysis, but did not induce significant changes in the TMZ IC50. Our results sup-
port the findings of Von Bueren et al. [36], who observed that TMZ resistance did not decrease
in medulloblastoma cell lines after MGMT inhibition with O6-BG treatment, and contrast
with that of Zhang et al. [37], who suggested that MGMT plays a critical role in TMZ resis-
tance. As such, other resistance mechanisms could play a part in modulating the efficacy of
TMZ in GBM cells.
The MMR complex is involved in repairing DNA damage caused by alkylating agents. Defi-
ciencies in the expression of MSH2, MSH6, and PMS2, which form part of the MMR complex,
have been linked to modulation of TMZ resistance independently of MGMT [30]. Indeed, Gas-
par et al. [28] correlated a high MMR complex expression with a low TMZ IC50 in the GBM
A172 cell line. In addition, Yip et al. [38] concluded that a decrease in MSH6 expression in a
clone taken from the A172 cell line correlated with TMZ resistance in comparison to the sensi-
tive A172 cell line which showed normal MSH6 expression. We analysed the presence of five of
the most important genes forming the MMR complex (MLH1, MSH2, MSH3, MSH6, and
PMS2) in our tumor cell lines before and after TMZ treatment. The results clearly showed that
cell lines with a high MGMT expression level and a high TMZ IC50 had a very low level of
MMR expression, whereas cell lines with no MGMT expression and a low TMZ IC50 were
characterized by high MMR expression levels. In addition, TMZ exposure induced a general
decrease in MMR expression in all tumor cells, with this decrease being most pronounced in
the A172 cell line (more than 80%). Although TMZ treatment increased expression of MSH3,
MSH6, and PMS2 in SF268 and SK-N-SH cell lines, the significant decrease in MLH1 and
MSH2 expression detected could explain the observed deficiency in MMR function. It is
known that MLH1 protein binds the MMR complex with to DNA after mismatch recognition
[39] and that MSH2 plays an important role in stabilizing MLH1 [40]. Interestingly, recent
studies demonstrated a strong association between some MMR complex subunits (such as
MLH1 expression), tumor recurrence, and TMZ resistance in GBM cell lines [38]. Thus, the
inability of TMZ cycles to modulate the IC50 in SF268 and SK-N-SH cell lines could be related
to a compensatory mechanism in which the decrease in MGMT expression (which increases
the cell's sensitivity to TMZ) is accompanied by a decrease in the levels of MMR complex,
thereby further increasing the cell’s resistance to TMZ. This could refute the classical concepts
in which TMZ resistance is only mediated by MGMT expression since a blockade of MGMT
does not affect the sensitivity to TMZ. Maxwell et al. [41] showed that patients with a high
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TMZ resistance have an altered MMR function, as determined by the reduced expression of
the MSH6 subunit. Hirose et al. [34] demonstrated that, in the GBM U87MG cell line (p53
wild-type phenotype), TMZ at 100 μM induced p53-dependent G2/M cell cycle arrest but did
not induce MGMT expression. This cell line showed similarities to the LN229 line. In contrast,
the A172 cell line (p53 mutated phenotype) has no pro-apoptotic activity [42]. This fact could
explain why A172 cells that presented low MMR expression levels after two TMZ cycles
(A172-2C) do not experience as much blockage in the G2/M phase, as alternative apoptosis
could occur in the p73 pathway [42]. On the other hand, the SF268 cell line (resistant to TMZ)
showed G2/M phase accumulation with no differences between basal and treated cells. This
could be justified by its mutated p53 phenotype and low level of MMR expression which pre-
vents the p73 apoptosis pathway [8]. SK-N-SH presented a p53 wild-type phenotype and a
blockage in the G2/M phase after TMZ treatment, but with no cell cycle modulation after drug
exposure [8]. As with SF268, the G2/M phase blockage may be related to the lower levels of
MMR, which is responsible for recognizing GT mismatches and triggering cell cycle arrest, cel-
lular senescence, and apoptosis in TMZ-treated cells [8].
Although P-gp has recently been associated with nervous system tumors [22,43], our analy-
ses showed no P-gp expression in either of the tumor cell lines studied, in agreement with the
limited data available with respect to GBM lines [44]. However, TMZ exposure increased P-gp
expression levels in all cell lines. To test the relevance of this molecule to resistance mecha-
nisms in GBM cells, we applied a TMZ treatment before and after verapamil exposure [45]. No
changes in TMZ IC50 were observed for A172 and LN229 cell lines (p = 0.3875). In contrast,
treatment with verapamil significantly increased the TMZ IC50 values for SF268 and SK-N-SH
(p = 0.0379 and p =< 0.0001, respectively). This seemingly contradictory result can be
explained by verapamil's ability to inhibit membrane calcium transporters [46]. In cells with
low levels of the MMR system (SF268 and SK-N-SH) apoptosis was mediated by intramito-
chondrial-calcium-dependent pathways (PARP, calpaina and AIF (parthanatos)) [47], thus
meaning that verapamil could block cell death. Indeed, A172 and LN229 cell lines (with high
MMR levels) did not reveal any TMZ IC50 modulation. Thus, P-gp does not appear to be
related to TMZ resistance in GBM patients.
Finally, the theory in which cytotoxic treatment selects resistant CSCs could explain post-
therapy cancer drug resistance. Although CSCs may be detected in different tumors, including
GBM, by the presence of CD133 [19], the value of the latter as a prognostic parameter is
unclear. Several in vivo studies have demonstrated that the presence of CSCs (CD133 positive)
in GBM correlated with chemoradioresistance and a poor prognosis [48], whereas Melguizo
et al. [11] recently demonstrated that CD133 has no implication in the prognosis of GBM
patients, supporting similar findings reported by Kim et al. [49]. Some authors even correlated
high expression of CD133 with a better GBM prognosis [50]. In this context, we studied
CD133+ population in our cell lines before and after TMZ treatment. CD133 expression has
been associated with drug resistance in SK-N-SH [51] and A172 cell lines [52]. Our results
showed a significant increase in the percentage of CD133+ cells after the first TMZ cycle in
A172 and LN229 cell lines. Interestingly, after treatment, both cell lines also showed a major
increase in the TMZ IC50. This CD133 population could make a moderate contribution to
increasing TMZ resistance during the treatment. On the other hand, the low percentage of
CD133+ cell population in SF268 and SK-N-SH basal cell lines could be indicative of an
unclear correlation between this population and initial TMZ resistance. However, TMZ caused
an clear enrichment of this population, suggesting that TMZ cycles treatment promoted the
generation of cancer stem cells.
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Conclusions
The molecular mechanisms mediating temozolomide resistance, one of the leading causes of
treatment failure in GBM patients, are unclear. As such, we used nervous system tumor cell
lines exposed to TMZ treatment to analyze the relevance of MGMT, the MMR system, and the
ABC transporter in the TMZ resistance phenomenon. Our results demonstrate that MGMT
does not play a key role in TMZ resistance in either A172 or LN229 cell lines (both with low
MGMT expression levels), and nor does it have an essential part in either SF268 or SK-N-SH
lines, both of which have high levels of MGMT expression. It is worth noting, however, that
the degree of MGMT expression correlates with expression of the MMR complex, which is also
modulated by TMZ. This may have a bearing on TMZ resistance and could explain the failure
of TMZ treatment in tumor cells with no MGMT expression. In contrast, the ABC-transport
protein P-gp does not appear to participate in TMZ drug resistance. Furthermore, we have
demonstrated that TMZ treatment produces a significant change in CD133+ cell percentages
in GMB cell lines. Further studies into CD133+ population characteristics in GMB cell lines
are necessary to determine the population's relevance to drug resistance and its differences
with respect to the negative CD133 cell population. Thus, therapeutic strategies that restore the
expression of the MMR system could lead to possible routes to improve the efficacy of TMZ
therapy in GBM patients.
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